Blepharitis, a chronic condition that causes inflammation of the eyelids, affects millions of people across the United States ...

Castor oil exposure significantly reduces survival of Demodex mites, offering a potential therapeutic benefit to patients with Demodex blepharitis.

Eyelash mites, microscopic arachnids, commonly reside on our faces, particularly around the eyes. While often harmless, an overgrowth can lead to Demodex blepharitis, causing itchy, red, and crusty ...

Here’s what eyelash mites really are, why they sometimes become a problem and how to prevent that from happening.

By Katherine Hamilton Viatris's said on Friday that the trial of an ointment for people with blepharitis didn't meet its primary endpoint.

Tarsus Pharmaceuticals' stock faces challenges despite XDEMVY's success. Analysts remain bullish with price targets of $72-$85. Read my updated TARS stock analysis.

Kate Middleton emotionally admitted during a hospital visit that she is "not able to function normally" after completing her cancer treatment.

Catherine, Princess of Wales, spoke during an appearance at a hospital about the trials of cancer treatment and readjusting to life afterward.

Palmer proclaimed that “princess treatment” makes her “feel special.” “Of course, I say ‘thank you’ and smile to whoever is serving us, etc. I’m not mute the entire evening out.

Effective treatment for Demodex blepharitis includes antibiotics, steroids, and lotilaner ophthalmic solution, which resolves symptoms and stabilizes refractive measurements. In nonsurgical patients, ...

A panelist discusses how treating demodex blepharitis with Lotilaner not only eliminates the anterior blepharitis symptoms but also improves meibomian gland function, with low recurrence rates after ...

OC50 2025 - Bobby Azamian of Tarsus Pharmacueticals. Spearheaded the development and commercialization of Xdemvy, the first FDA-approved treatment for Demodex blepharitis.